WO2002003956A1 - Cough treatment - Google Patents

Cough treatment Download PDF

Info

Publication number
WO2002003956A1
WO2002003956A1 PCT/US2001/020495 US0120495W WO0203956A1 WO 2002003956 A1 WO2002003956 A1 WO 2002003956A1 US 0120495 W US0120495 W US 0120495W WO 0203956 A1 WO0203956 A1 WO 0203956A1
Authority
WO
WIPO (PCT)
Prior art keywords
cough
person
treatment
need
tongue
Prior art date
Application number
PCT/US2001/020495
Other languages
French (fr)
Inventor
John David Hull
Paul John Rennie
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to AU2001271537A priority Critical patent/AU2001271537A1/en
Publication of WO2002003956A1 publication Critical patent/WO2002003956A1/en
Priority to US10/336,909 priority patent/US20030104038A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the present invention relates to methods and devices for treating cough, in particular in which' a person in need of cough treatment is provided with a buccally adherent patch and is instructed to stimulate the patch when feeling a need to cough.
  • Cough is a protective mechanism to guard the airways from irritants.
  • pathological cough can be irritating, stressful and non-beneficial both physiologically and socially.
  • People suffering from coughing commonly take cough syrups, drops or lozenges, for symptomatic relief.
  • prescription drugs may be used to control the symptoms. It is commonly accepted that coughing, and the throat irritation associated with it, can be treated by lubrication with sweet and viscous syrups. Thus, for example, cough drops or lozenges often contain sugar or honey. Active ingredients can also be incorporated into the syrups or lozenges.
  • active ingredients include, for example, antitussives, which can act to suppress the cough reflex, such as dextromethorphan and its hydrobromide salt; expectorants, such as guaifenesin, which make the cough more productive; and other agents such as coolants which may act by relieving the throat irritation, menthol, peppermint oil and the like are well known in this regard, other physiological coolants such as menthane carboxamides are also useful in this regard.
  • antitussives which can act to suppress the cough reflex
  • expectorants such as guaifenesin, which make the cough more productive
  • other agents such as coolants which may act by relieving the throat irritation, menthol, peppermint oil and the like are well known in this regard, other physiological coolants such as menthane carboxamides are also useful in this regard.
  • the present invention relates to a method of treating cough comprising:
  • the present invention further relates to the use of a mucoadhesive polymer in the manufacture of a device for the treatment of cough, the treatment comprising:
  • the methods of the invention of the invention utilise a device which is attached to the interior of the oral cavity of a person in need of cough treatment.
  • the precise nature of the device, and the material from which it is made, is not critical. Clearly it should be safe for use in the oral cavity. That is it should preferably be free of sharp edges and should not cause obstruction of the airway if swallowed. Further, since it is intended that the person in need of treatment will carry the device in their mouth for a considerable period of time, the device should feel comfortable in the mouth and not, for example, cause 'gagging'.
  • the device is a mucoadhesive gel patch or disc, made entirely from food grade materials such as gelatin, having a thickness of from 1 - 2 mm and a diameter of from 1 mm to 1 cm.
  • the disc can be a laminated device having, for example a water insoluble layer and a mucoadhesive layer. Discs are preferred because of their lack of corners, but the shape is not especially important. Other possible shapes include squares, strips and hoops.
  • the device can optionally be textured, especially on the face directed to the interior of the oral cavity, so that it feels rough to the tongue, in order to provide greater stimulation when touched.
  • Suitable mucoadhesive polymers for use in the manufacture of the device include polysaccharides such as for example cellulose-type materials and natural gums, polypeptides, and water-soluble synthetic polymers.
  • suitable polymers which are GRAS certified include poly(vinyl pyrrolidone) ("PVP"), poly(vinyl alcohol) (“PVA”), hydroxy propyl cellulose (“HPC”), polyethylene oxide) (“PEO”), poly(acrylic acid) (“PAA”), polyacrylates such as Carbopol 934 (B. F. Goodrich), starch and starch derivatives, polysaccharides, sodium carboxymethyl cellulose ("Na-CMC”), xanthan gum, karaya gum, and gelatin, among others. Preferred is gelatin.
  • Suitable devices are disclosed in US 5,700,478 which is incorporated herein by reference in its entirety. Other suitable devices are available from 3M as the Cydot® TMD System. WO93/23011 also discloses suitable devices and is incorporated herein by reference in its entirety.
  • the devices of the invention need not contain any active ingredients since they are particularly intended to trigger natural physiological control mechanisms in the human cerebral cortex to control the cough reflex. It is recognised however that drug based remedies may further enhance their efficacy in controlling cough and any of the usual cough actives known to the skilled person can also be incorporated into the device.
  • useful active agents are antitussives, which can act to suppress the cough reflex, such as dextromethorphan and its hydrobromide salt; and expectorants, such as guaifenesin.
  • plasticisers such as glycerin, sorbitol, and other edible polyhydric alcohols
  • flavours and other organoleptic stimulants such as physiological cooling and / or warming agents to make the device more palatable in the mouth or to increase the stimulation when the patch is touched
  • antibacterial agents such as triclosan or quaternary ammonium salts which can help to reduce associated infections.
  • the devices are preferably sugar-free.
  • the basic method of treatment involves attaching the device to the interior of the oral cavity of a person in need of cough treatment and providing instructions to the person to stimulate the device as necessary, in particular when the person feels a need or an incipient need to cough.
  • the preferred method of stimulating the device is for the person to touch the device with their tongue when they feel the need to cough. In doing so the person's tongue is in turn stimulated providing a physiological feedback.
  • the device can be attached to the oral cavity by any safe method but it is preferred to attach it by adhesion, through the use of a mucoadhesive polymer as described above.
  • the device is suitably attached in any position where it can be stimulated by the tongue, and preferably by the tip of the tongue.
  • Suitable locations include on the teeth, on the hard palate the inside of the lips and the inside of the cheek, the inside of the cheek being preferred.
  • the instructions are included with the device, for example by way of a kit comprising device and instructions, for the person to touch the device with their tongue when they feel the need to cough.
  • the devices can be manufactured using art-known methods such as the drying down of an aqueous solution of a polymer until a plastic disc or sheet is obtained, or by using any of the methods described in the references above.
  • a set of flexible gel discs of about 1 cm in diameter and 1 mm thickness were prepared from a 38% solution of Gelatin Bloom 220 in water.
  • a group often people suffering from cough were asked to stick a gel disc to the inner, right-hand side of their cheek and to keep the disc in position without sucking or chewing on the disc. They were then instructed "When you feel a cough coming on, instead of coughing, touch the disc with your tongue”.
  • a lower frequency of coughing was recorded within the group than a control group of cough sufferers who were instructed "You have been allocated not to take anything for your cough”.

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to methods and devices for treating cough, in particular in which a person in need of cough treatment is provided with a buccally adherent patch and is instructed to stimulate the patch when feeling a need to cough. The invention works through triggering natural physiological control mechanisms in human cerebral cortex to control the cough reflex.

Description

Cough Treatment
Field of the Invention
The present invention relates to methods and devices for treating cough, in particular in which' a person in need of cough treatment is provided with a buccally adherent patch and is instructed to stimulate the patch when feeling a need to cough.
Background Of The Invention
Cough is a protective mechanism to guard the airways from irritants. However, pathological cough can be irritating, stressful and non-beneficial both physiologically and socially. People suffering from coughing commonly take cough syrups, drops or lozenges, for symptomatic relief. In some cases, prescription drugs may be used to control the symptoms. It is commonly accepted that coughing, and the throat irritation associated with it, can be treated by lubrication with sweet and viscous syrups. Thus, for example, cough drops or lozenges often contain sugar or honey. Active ingredients can also be incorporated into the syrups or lozenges. These active ingredients include, for example, antitussives, which can act to suppress the cough reflex, such as dextromethorphan and its hydrobromide salt; expectorants, such as guaifenesin, which make the cough more productive; and other agents such as coolants which may act by relieving the throat irritation, menthol, peppermint oil and the like are well known in this regard, other physiological coolants such as menthane carboxamides are also useful in this regard.
Other delivery vehicles that have been used to deliver cough actives include chewing gums, such as those disclosed in U.S. patent no. 5,846,557, and mucoadhesive devices such as those disclosed in PCT publication WO 95/05416.
In spite of the many products and disclosures relating to cough treatment the present inventors believe that insufficient attention has been paid to the importance of the cortical control of cough. The present inventors have found that physical contact with a buccally adhered device triggers natural physiological control mechanisms in human cerebral cortex to control the cough reflex.
It is therefore an object of the present invention to provide a method and devices for the treatment of cough, more particularly to a method, and devices for use in the method, which activates or enhances the cortical control of cough.
These objectives will become readily apparent from the detailed description which follows.
Summary Of The Invention
The present invention relates to a method of treating cough comprising:
(a) attaching a device to the interior of the oral cavity of a person in need of cough treatment;
(b) providing instructions to the person to stimulate the device as necessary.
The present invention further relates to the use of a mucoadhesive polymer in the manufacture of a device for the treatment of cough, the treatment comprising:
(a) attaching the device to the interior of the oral cavity of a person in need of cough treatment;
(b) providing instructions to the person to stimulate the device as necessary.
All percentages and ratios herein are by weight unless otherwise specified. Percentages are by weight of the total composition unless otherwise specified.
Detailed Description Of The Invention
The essential as well as optional components of the compositions of the present invention are described in the following paragraphs.
Device
The methods of the invention of the invention utilise a device which is attached to the interior of the oral cavity of a person in need of cough treatment. The precise nature of the device, and the material from which it is made, is not critical. Clearly it should be safe for use in the oral cavity. That is it should preferably be free of sharp edges and should not cause obstruction of the airway if swallowed. Further, since it is intended that the person in need of treatment will carry the device in their mouth for a considerable period of time, the device should feel comfortable in the mouth and not, for example, cause 'gagging'.
In the preferred practise of the invention the device is a mucoadhesive gel patch or disc, made entirely from food grade materials such as gelatin, having a thickness of from 1 - 2 mm and a diameter of from 1 mm to 1 cm. Alternately, the disc can be a laminated device having, for example a water insoluble layer and a mucoadhesive layer. Discs are preferred because of their lack of corners, but the shape is not especially important. Other possible shapes include squares, strips and hoops. The device can optionally be textured, especially on the face directed to the interior of the oral cavity, so that it feels rough to the tongue, in order to provide greater stimulation when touched.
Suitable mucoadhesive polymers for use in the manufacture of the device include polysaccharides such as for example cellulose-type materials and natural gums, polypeptides, and water-soluble synthetic polymers. Particular examples of such suitable polymers which are GRAS certified include poly(vinyl pyrrolidone) ("PVP"), poly(vinyl alcohol) ("PVA"), hydroxy propyl cellulose ("HPC"), polyethylene oxide) ("PEO"), poly(acrylic acid) ("PAA"), polyacrylates such as Carbopol 934 (B. F. Goodrich), starch and starch derivatives, polysaccharides, sodium carboxymethyl cellulose ("Na-CMC"), xanthan gum, karaya gum, and gelatin, among others. Preferred is gelatin.
Suitable devices are disclosed in US 5,700,478 which is incorporated herein by reference in its entirety. Other suitable devices are available from 3M as the Cydot® TMD System. WO93/23011 also discloses suitable devices and is incorporated herein by reference in its entirety.
The devices of the invention need not contain any active ingredients since they are particularly intended to trigger natural physiological control mechanisms in the human cerebral cortex to control the cough reflex. It is recognised however that drug based remedies may further enhance their efficacy in controlling cough and any of the usual cough actives known to the skilled person can also be incorporated into the device. Among useful active agents are antitussives, which can act to suppress the cough reflex, such as dextromethorphan and its hydrobromide salt; and expectorants, such as guaifenesin.
Other suitable components can include plasticisers, such as glycerin, sorbitol, and other edible polyhydric alcohols; flavours and other organoleptic stimulants such as physiological cooling and / or warming agents to make the device more palatable in the mouth or to increase the stimulation when the patch is touched; and antibacterial agents such as triclosan or quaternary ammonium salts which can help to reduce associated infections. The devices are preferably sugar-free.
Methods of treatment and manufacture
The basic method of treatment involves attaching the device to the interior of the oral cavity of a person in need of cough treatment and providing instructions to the person to stimulate the device as necessary, in particular when the person feels a need or an incipient need to cough. The preferred method of stimulating the device is for the person to touch the device with their tongue when they feel the need to cough. In doing so the person's tongue is in turn stimulated providing a physiological feedback.
The device can be attached to the oral cavity by any safe method but it is preferred to attach it by adhesion, through the use of a mucoadhesive polymer as described above.
The device is suitably attached in any position where it can be stimulated by the tongue, and preferably by the tip of the tongue. Suitable locations include on the teeth, on the hard palate the inside of the lips and the inside of the cheek, the inside of the cheek being preferred.
In the preferred method the instructions are included with the device, for example by way of a kit comprising device and instructions, for the person to touch the device with their tongue when they feel the need to cough. The devices can be manufactured using art-known methods such as the drying down of an aqueous solution of a polymer until a plastic disc or sheet is obtained, or by using any of the methods described in the references above.
The following examples further describes and demonstrate preferred embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations of this invention.
Example
A set of flexible gel discs of about 1 cm in diameter and 1 mm thickness were prepared from a 38% solution of Gelatin Bloom 220 in water. A group often people suffering from cough were asked to stick a gel disc to the inner, right-hand side of their cheek and to keep the disc in position without sucking or chewing on the disc. They were then instructed "When you feel a cough coming on, instead of coughing, touch the disc with your tongue". A lower frequency of coughing was recorded within the group than a control group of cough sufferers who were instructed "You have been allocated not to take anything for your cough".

Claims

Claims
1. A method of treating cough comprising: a) attaching a device to the interior of the oral cavity of a person in need of cough treatment; b) providing instructions to the person to stimulate the device as necessary.
2. A method according to Claim 1 wherein the device is a food-grade, mucoadhesive patch.
3. A method according to Claim 1 or Claim 2 comprising instructing the person to touch the device with their tongue when they feel the need to cough.
4. A method according to any preceding claim wherein the device comprises a mucoadhesive polymer, preferably gelatin.
5. Use of a mucoadhesive polymer in the manufacture of a device for the treatment of cough, the treatment comprising: a) attaching the device to the interior of the oral cavity of a person in need of cough treatment; b) providing instructions to the person to stimulate the device as necessary.
6. Use according to Claim 5 wherein the mucoadhesive polymer is gelatin.
7. Use according to Claim 5 or Claim 6 wherein the treatment comprises instructing the person to touch the device with their tongue when they feel the need to cough.
8. A device for the treatment of cough, the device comprising a mucoadhesive polymer and the treatment comprising: a) attaching the device, via the mucoadhesive polymer, to the interior of the oral cavity of a person in need of cough treatment; and b) providing instructions to the person to stimulate the device as necessary.
9. A device according to Claim 8 or for use in any preceding method or manufacture which has a textured surface which feels rough to the tongue.
PCT/US2001/020495 2000-07-07 2001-06-27 Cough treatment WO2002003956A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001271537A AU2001271537A1 (en) 2000-07-07 2001-06-27 Cough treatment
US10/336,909 US20030104038A1 (en) 2000-07-07 2003-01-06 Cough treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016693.4 2000-07-07
GBGB0016693.4A GB0016693D0 (en) 2000-07-07 2000-07-07 Cough treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/336,909 Continuation US20030104038A1 (en) 2000-07-07 2003-01-06 Cough treatment

Publications (1)

Publication Number Publication Date
WO2002003956A1 true WO2002003956A1 (en) 2002-01-17

Family

ID=9895199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020495 WO2002003956A1 (en) 2000-07-07 2001-06-27 Cough treatment

Country Status (4)

Country Link
AU (1) AU2001271537A1 (en)
GB (1) GB0016693D0 (en)
PE (1) PE20020142A1 (en)
WO (1) WO2002003956A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096174A1 (en) * 2003-04-25 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing pharmaceutically active agents
WO2018032121A1 (en) * 2016-08-16 2018-02-22 胡斌 Electret film for treating cough caused by increased cough reflex sensitivity, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
WO1995005416A2 (en) 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5846557A (en) 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
WO1995005416A2 (en) 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5700478A (en) 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5846557A (en) 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096174A1 (en) * 2003-04-25 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing pharmaceutically active agents
CN1750809B (en) * 2003-04-25 2010-05-26 沃尼尔·朗伯有限责任公司 Fast dissolving orally consumable films containing pharmaceutically active agents
WO2018032121A1 (en) * 2016-08-16 2018-02-22 胡斌 Electret film for treating cough caused by increased cough reflex sensitivity, and use thereof

Also Published As

Publication number Publication date
PE20020142A1 (en) 2002-03-13
GB0016693D0 (en) 2000-08-23
AU2001271537A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
US9161909B2 (en) Adhesive compositions for the treatment of xerostomia
US9549842B2 (en) Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8978659B2 (en) Therapeutic and protective dental device useful as an intra-oral delivery system
US8701671B2 (en) Non-surgical method and system for reducing snoring
AU2011100027A4 (en) Nicotine containing soft gelatin pastilles
CN110996891B (en) Gel comprising chlorhexidine
WO1996034608A1 (en) Oral lubricating composition comprising a beta-glucan
WO2003003957A1 (en) Quick dissolving oral mucosal drug delivery device with moisture barrier coating
JPH11514967A (en) Use of hyaluronic acid and NSAIDs for the manufacture of a medicament for the treatment of mucosal inflammation
US20140161744A1 (en) Composition with activated carbon in oral treatment
AU2004233742A1 (en) Confectionery products for delivery of pharmaceutically active agents to the throat
US20090053309A1 (en) Adhesive compositions for the treatment of xerostomia
WO2007046890A1 (en) Lozenge for treatment of dry mouth and related conditions
US20060251704A1 (en) Methods and devices for efficacious treatment of aphthous ulcers
US20020198552A1 (en) Intraoral hygiene device
US20030104038A1 (en) Cough treatment
WO2002003956A1 (en) Cough treatment
US20220323343A1 (en) Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia
RU2685506C2 (en) Lubricating composition for mouth
JP4909809B2 (en) Artificial saliva
JP7537764B2 (en) Adhesive Pad
US5409691A (en) Solution comprising aluminum acetate and glycerin
US20180214762A1 (en) Protective and healing inner cheek pads
JP4804420B2 (en) Artificial saliva
US20100092543A1 (en) Dimpled adhering troche for use on teeth or orthodontic braces

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10336909

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP